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See Article, pages 666–673Hepatic impairment resulting from the use of conventional drugs
is widely acknowledged, but there is less awareness of the poten-
tial hepatotoxicity of alternative medicines such as herbal prepa-
rations [1]. The increasing attraction for herbals medicines is
partly explained by the return to natural products occurring
along with the ecological movement in industrialized countries
[1]. It is also related to the limited efﬁcacy or the important side
effects of treatments of various chronic diseases [1–5]. Several
recent studies that focused on the use of herbal medicines in
chronic hepatitis C are particularly demonstrative in Western
countries [6,7]. A prospective inquiry carried out in France, based
on outpatients seen for chronic liver diseases, has revealed that
there was a herbal medicine intake for at least 1 month in 30%
of included patients with hepatitis C [6]. Similarly, the hepatitis
C antiviral long-term treatment against cirrhosis (HALT-C) trial
conducted in the USA showed that 21% of enrolled patients had
taken herbal medicines before and 23% at the time of inclusion
[7]. In both studies, the most commonly used herbal compounds
were sylimarin and valerian [6,7]. The use of herbal medicines
does not require any medical prescription. Patients may ﬁnd
these products in various stores, some of them being specialized
in herbal products but also in pharmacy stores. Furthermore, the
possibility to get herbal products via the internet has markedly
contributed to the increase in their sales [4]. In several areas of
the world, particularly in Asia, Africa, and central and South
America, the use of herbal medicines is an important part of a tra-
ditional medicine exhibiting several advantages, in particular,
easy availability and low cost [1–5].
Over the last decades it has become apparent that herbal
medicines may cause a very large spectrum of liver injury, affect-
ing all cells present in the liver and biliary tree, and ranging from
mild asymptomatic liver enzyme elevation to acute hepatitis,
chronic hepatitis, cirrhosis, liver failure, acute and chronic cho-
langitis, macro- and micro-vesicular steatosis, and vascular
lesions [1–5]. Furthermore, herbal medicines may produce inter-
actions with liver drug metabolizing enzymes [2]. A representa-
tive instance is St. John’s Wort (Hypericum perforatum L.) whichJournal of Hepatology 20
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the metabolism of several immunosuppressive agents such as
cyclosporine and tacrolimus [2].
To avoid these side effects, utilization of ‘‘natural medicine’’ is
increasingly controlled in many countries. Marketing authoriza-
tion has been given for plants considered efﬁcient and innocuous.
Indeed, in most cases, the efﬁciency and safety have been based
more on a reputation acquired over the centuries rather than
on controlled trials and toxicity studies [1–5].
Hepatotoxicity of herbal remedies is particularly difﬁcult to
demonstrate [8]. Indeed, in addition to the usual difﬁculties
found while assessing the relationship between an adverse event
and the intake of a drug largely caused by the absence of clinical
speciﬁcity [8], there may be difﬁculties with frequent auto-
medication and the reputation of safety so that the patient often
forgets to mention herbal medicine ingestion to the physician
[4,5,8]. In addition, there are speciﬁc risks contributing to the
hepatotoxicity of herbal remedies [4]: misidentiﬁcation of the
plant, selection of a wrong part of the medicinal plant, inadequate
storage modifying the native product, adulteration during pro-
cessing, and mislabeling of the ﬁnal product [4]. For instance,
some Asian preparations contain more than 10 different plants
[1–5]. Another instance is Herbalife hepatotoxicity recently
reported in Israel and Switzerland [9,10]. Interestingly, it seems
that the complex composition of the products marketed under
this brand name in these two countries was not exactly similar
[9,10]. Another difﬁculty is that the real composition of the her-
bal preparation may remain unclear [1–5]. A safe herbal product
may be contaminated by toxic compounds leading to hepatotox-
icity. This is the case with heavy metals, pesticides, herbicides,
microorganisms, and even classical pharmaceutical products
[1–5]. A recent illustration is a product marketed in Scandinavian
countries under the brand name Fortodol, normally containing
Curcuma longa (turmeric) as a gentle pain killer [11]. The occur-
rence of several cases of liver injury led to analyze the composi-
tion of this apparently innocuous product. It turned out that it
also contained nimesulide, a non-steroidal anti-inﬂammatory
compound, well documented to cause acute liver injury [11].
To date, around ﬁfty medicinal preparations have been
reported to be toxic to the liver [1–5]. The degree of evidence
for toxicity is as variable as is for classical pharmaceutical agents.
Herbal medicines with the highest level of evidence for
hepatotoxicity are plants containing pyrrolizidine alkaloids,11 vol. 54 j 599–601
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germander (Teucrium chamaedris), Atractylis gummifera, plants
containing pennyroyal oil (Mentha pulegium, Hedeoma pulegio-
ides), great celandine (Chelidonium majus), kava–kava ( Piper
methysticum), and several Asian medicinal preparations [1–5].
Other compounds for which a fair level of evidence exists for hep-
atotoxicity are chaparral leaf (Larrea tridentata), senna (Cassia
angustifolia), hydroalcoholic extracts of green tea and Herbalife
[1–5,9,10].
Pyrrolizidine alkaloids make up a remarkable illustration of
the difﬁculties encountered with herbal medicine hepatotoxicity
and the particular need to have biomarkers to overcome them.
These alkaloids are found in more than 6000 plants worldwide
[12]. The main implicated species are: Heliotroprium, Senecio,
Crotalaria [17], and Symphytum (Comfrey) [1–5,12] but also Gyn-
ura segetum as illustrated in the report by Lin et al. in this issue of
the Journal [13].
Pyrrolizidine poisoning is endemic in areas such as Africa and
Jamaica, where toxic alkaloids are ingested as infusions, herbal
teas, decoctions, or used as an enema [1–5]. Contamination of
four by plants containing pyrrolizidine alkaloids has also caused
epidemic intoxications in India and Afghanistan [1–5]. Pyrrolizi-
dine alkaloids are also a concern for Chinese herbal medicines
[13]. In the Journal, Lin et al. report at least 51 cases with
‘‘Tusanqi’’ traditional preparation [13] and stress that there are
probably many more cases [13]. Hepatotoxicity occurs because
of the misuse of G. segetum instead of non-toxic plants in the
preparation.
The main liver injury induced by pyrrolizidine alkaloids is
veno-occlusive disease, the so-called hepatic sinusoidal obstruc-
tion syndrome (HSOS) [2–5,14,15]. Pyrrolizidine alkaloids account
for more than 8000 cases of HSOS worldwide and make up one of
the major causes of this syndrome [1–5,14,15]. HSOS brings about
hepatic congestion, which may lead to parenchymal necrosis. In
some cases, ﬁbrosis and even cirrhosismay develop. Different clin-
ical subtypes have been described [4,14,15]. The acute form is
characterized by markedly increased serum aminotransferase
activities. When lesions are extensive, hepatic failure may occur,
leading to death [4,14,15]. In contrast, the chronic form insidiously
develops and may mimic cirrhosis. One fatal case of veno-
occlusive disease has been described in a newborn infant whose
mother had been exposed to a plant containing pyrrolizidine alka-
loids during pregnancy [16].
Hepatotoxicity of pyrrolizidine alkaloids is reproducible and
dose-related in laboratory animals [1–5]. It has been related to
the biotransformation of unsaturated alkaloids into unstable,
toxic metabolites, probably pyrrolic derivatives, by cytochrome
P-450 leading mainly to lesions of endothelial cells and to a lesser
extent of hepatocytes [1–5]. Up to now, however, there was no
means for providing direct evidence of the direct role of pyrrolizi-
dine alkaloids in a clinical situation.
Lin et al. have reached this new step [13]. Indeed, they have
constructed a sensitive and speciﬁc assay enabling for the detec-
tion of a reactive pyrrole–protein adduct in serum [13]. This assay
was used to show the presence of the reactive adduct directly in
the serum of a patient with HSOS related to the Tusanqi prepara-
tion made erroneously with G. segetum instead of Sedum aizoon
[13]. In addition, an animal study further showed the good
correlation of liver injury with the ingestion of G. segetum [13].
This is the second instance in which a biomarker provides
evidence for the role of a plant in a patient with liver injury.
The other example of a diagnostic biomarker but with less direct600 Journal of Hepatology 201evidence is germander (T. chamaedris) which has been responsi-
ble for numerous cases of liver injury [4,17]. Germander
hepatotoxicity has been reproduced in mice and is dose-
dependent [4]. The chemical composition of germander comprises
furan-containing neoclerodane diterpenoids. Germander compo-
nents are oxidized by cytochrome P4503A into reactive metabo-
lites [18]. These reactive metabolites deplete glutathione and
cytoskeleton-associated protein thiols, form plasma membrane
blebs, and cause apoptosis contributing to liver cell death [4,19].
Finally, reactive metabolites could trigger hepatotoxicity through
an immunoallergic reaction [20]. Indeed, anti-microsomal epoxide
hydrolase autoantibodies have been found in the sera of patients
who drank germander teas for a long period of time [20]. This
serum antibodymakes up a biomarker allowing for the correlation
of cases of liver injury with germander ingestion.Conclusion
Herbal medicines are increasingly recognized as causes of liver
injury. Advances in the understanding of pathogenesis are
needed to improve herbal medicine safety. The development of
speciﬁc biomarkers is a key step to allow more accurate
diagnoses and gain crucial information on complex medicinal
preparation.Conﬂict of interest
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